ReForm Biologics, MilliporeSigma ink license agreement

By The Science Advisory Board staff writers

February 10, 2020 -- ReForm Biologics and MilliporeSigma have signed a licensing agreement to develop and market excipients used for biotherapeutic applications.

The agreement dictates that the two firms will research and develop ReForm Biologics' excipients for pharmaceutical use, with MilliporeSigma funding the effort and taking responsibility for global marketing, manufacturing, and sale of the excipients to its customers. ReForm Biologics will receive revenues from MilliporeSigma for sublicensing ReForm Biologics' technology, it said.


Copyright © 2020 scienceboard.net
 


MemberID or email address:

Password:
Forgot your password?